YN001-004 in Patients With Coronary Atherosclerosis in Australia
NCT ID: NCT06700720
Last Updated: 2026-01-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
24 participants
INTERVENTIONAL
2026-01-31
2026-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of MEDI6570 in Patients With a History of Myocardial Infarction
NCT04610892
A Double-Blind Study of E5555 in Japanese Subjects With Coronary Artery Disease
NCT00540670
Study of ONO-1101 in Patients Scheduled for Coronary Angiography
NCT00560209
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
NCT03872401
Effect of Evolocumab on Vascular Function
NCT03626831
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A total of 24 patients with coronary atherosclerosis are expected to be enrolled and will be randomly assigned in a 1:1 ratio to 1 of 2 YN001 treatment arms (12 patients per arm) with 2 different dose levels for 12 weeks.
The study will be comprised of a maximum 41-day screening period (Day -42-Day -2), a baseline period (Day-1), a treatment and observation period (W1D1- W13D7), and a safety follow-up period (14 days post last dose).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dose 1 treatment arm
Dose 1 YN001 will be administrated intravenously weekly.
Dose 1 YN001
Dose 1 YN001 will be administered on Day 1 of each week from Week 1 to Week 13, 13 times in total.
Evolocumab
Evolocumab 140 mg will be administered subcutaneously every 2 weeks.
Dose 2 treatment arm
Dose 2 YN001 will be administrated intravenously weekly.
Dose 2 YN001
Dose 2 YN001 will be administered on Day 1 of each week from Week 1 to Week 13, 13 times in total.
Evolocumab
Evolocumab 140 mg will be administered subcutaneously every 2 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dose 1 YN001
Dose 1 YN001 will be administered on Day 1 of each week from Week 1 to Week 13, 13 times in total.
Dose 2 YN001
Dose 2 YN001 will be administered on Day 1 of each week from Week 1 to Week 13, 13 times in total.
Evolocumab
Evolocumab 140 mg will be administered subcutaneously every 2 weeks.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Male or female Australia patients between 18 and 75 years.
3. Patients diagnosed with coronary atherosclerosis, and at least 1 vessel with diameter stenosis determined by coronary computed tomography angiography (CTA).
4. Female patients must be non-pregnant and non-lactating, and females of childbearing potential (including a female partner of a male patient) must agree to use 1 effective contraception method from the screening period to 3 months after receiving their last dose of the study drug. In addition, male patients must be willing to refrain from sperm donation during this time.
5. Willing and able to comply with the requirements of protocol to the best of the patient's and investigator's knowledge.
Exclusion Criteria
2. Previously received YN001.
3. Any type of vaccination within 4 weeks prior to randomization.
4. Contraindication for coronary CTA (e.g., known history of anaphylactic contrast reactions).
5. Multi-vessel severe disease.
6. Recent acute ST-segment elevation myocardial infarction (STEMI) occurred within 2 weeks prior to randomization.
7. Relapse and highly symptomatic arrhythmia uncontrolled by drugs within the past 3 months, such as ventricular tachycardia, atrial fibrillation with rapid ventricular rate and paroxysmal supraventricular tachycardia.
8. Prior treatment with CABG, heart transplantation, SAVR/TAVR, etc., or CABG, heart transplantation, SAVR/TAVR, etc., is required or planned during the study.
9. PCI performed within 4 weeks prior to randomization or PCI is required or planned during study treatment.
10. New York Heart Association (NYHA) class III or IV, or last known left ventricular ejection fraction (LVEF) \<40%.
11. Recent clinically evident stroke occurred within 6 months prior to randomization (except for TIA).
12. Presenting with history of myopathy/myalgia, or susceptible to myopathy/rhabdomyolysis.
13. Known inflammatory bowel disease, ulcers, gastrointestinal or rectal bleeding within 6 months prior to randomization.
14. Evidence of major diseases that not recovered within 2 weeks prior to randomization, or major surgery is expected during the study.
15. Presenting with history of malignancy (except in patients who have been disease-free \>5 years; or whose only malignancy has been basal or squamous cell skin carcinoma).
16. Presence of any type of autoimmune disease.
17. Allergy to multiple food or drugs or known sensitivity to any components to be administered during dosing
18. Life expectancy is less than 1 year.
19. Systolic blood pressure of ≥150 mmHg at final screening despite antihypertensive therapy.
20. Known familial hypercholesterolemia
21. Triglycerides≥400 mg/dl (4.5 mmol/l) at final screening.
22. Active liver disease or hepatic dysfunction defined by any of ALT, AST, or total bilirubin \> 2 times upper limit of normal (ULN) at final screening.
23. Presence of renal insufficiency.
24. Untreated or inadequately treated hypothyroidism defined by thyroid stimulating hormone (TSH) \> 1.5 times ULN at final screening.
25. Poorly controlled (defined by HbA1c \> 9%) type 2 diabetes mellitus.
26. A positive hepatitis B surface antigen (HBsAg), or positive antibody against hepatitis C virus (anti-HCV) or human immunodeficiency virus (anti-HIV), or positive treponema pallidum antibody (TP-Ab).
27. Current smoker who has smoked an average of≥5 cigarettes (or equivalent) per day over the preceding year.
28. Presence of any other diseases or conditions (apart from those outlined above) that, in the opinion of the investigator, would make it unsuitable for the patient to participate in this study.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beijing Inno Medicine Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Teresa Chen, PhD
Role: STUDY_DIRECTOR
Beijing Inno Medicine Co., Ltd.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Canberra Hospital
Canberra, Australian Capital Territory, Australia
Albury Wodonga Private Hospital
Albury, New South Wales, Australia
Sunshine Coast University Private Hospital
Birtinya, Queensland, Australia
Core Research Group Pty Ltd
Milton, Queesland, Australia
Altona Clinical Research
Melbourne, Victoria, Australia
Peninsula Heart Centre
Melbourne, Victoria, Australia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Walter Abhayaratna, PhD
Role: primary
Fiore
Role: primary
Thackwray
Role: primary
Walsh
Role: primary
Szto
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
YN001-004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.